Santa Monica, CANCT06607458Now EnrollingIRB Ready

Refractory Metastatic Colorectal Cancer Clinical Trial in Santa Monica, CA

Access cutting-edge refractory metastatic colorectal cancer treatment through this clinical trial at a research site in Santa Monica. Study-provided care at no cost to qualified participants.

Sponsored by Delcath Systems Inc.

Quick Self-Assessment

See if you qualify for this Santa Monica location

Preparing your pre-screening questions…

Expert Care in Santa Monica

Access refractory metastatic colorectal cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related refractory metastatic colorectal cancer treatment provided free

Apply for This Santa Monica Location

Check if you qualify for this refractory metastatic colorectal cancer clinical trial in Santa Monica, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Santa Monica

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Santa Monica site if eligible
  4. 4Begin participation

About This Refractory Metastatic Colorectal Cancer Study in Santa Monica

The goal of this clinical trial is to learn if using a liver-directed therapy with high dose chemotherapy followed by approved cancer treatment to treat patients with colorectal cancer that has spread to the liver is safe and tolerable. The clinical trial will also learn if the liver-directed therapy with high dose chemotherapy works on the disease in the liver. Investigators will compare the use of the liver-directed therapy with high dose chemotherapy followed by approved cancer treatment or approved cancer treatment alone. Participants will: * Undergo up to two liver-directed therapy with high dose chemotherapy procedures followed by approved cancer treatment or take approved cancer treatment alone * Visit clinic at least every two weeks for checkups and tests * Complete scans approximately every two months

Sponsor: Delcath Systems Inc.

Who Can Participate

Inclusion Criteria

Histologically confirmed diagnosis of metastatic colorectal cancer and histologically or cytologically proven CRC metastases that occupy 50% or less of the liver parenchyma.
Patient has liver-dominant metastatic disease. Liver-dominant is defined as the majority of total tumor burden is located in the liver, and the liver lesions are not resectable or treatable with ablation or are associated with extrahepatic disease that makes surgical intervention non-curative.
Disease in the liver must be measurable (per RECIST v.1.1 guidelines) by computed tomography (CT) and/or magnetic resonance imaging (MRI).
If there is evidence of extrahepatic metastatic disease, it is limited, and the life-threatening component of disease is in the liver. Limited extrahepatic disease is defined in this protocol as follows: up to 5 tumor lesions in the lung with longest diameter not greater than 2 cm and/or up to 5 lymph nodes that measure 2 cm or less per lesion; solitary lesions definitively treated with no sign of progression in the last 6 months.
Scans used to determine eligibility (CT scan of the chest/abdomen/pelvis and MRI of the liver) must be performed within 28 days prior to randomization.
Previous treatment and progressed on or following, or intolerant to, fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and/or an anti-EGFR therapy if RAS wild-type.
ECOG PS of 0-1 within 14 days prior to randomization.

Exclusion Criteria

Child-Pugh Class B or C cirrhosis or evidence of clinically significant portal hypertension by history, endoscopy, or radiologic studies (large abdominal varices, prior history of varices by endoscopy).
New York Heart Association functional classification II, III or IV or active cardiac condition(s), including unstable coronary syndromes (unstable or severe angina, recent myocardial infarction), worsening or new-onset congestive heart failure, significant arrhythmias, or severe valvular disease that create(s) undue risks of undergoing general anesthesia.
History or evidence of clinically significant pulmonary disease that precludes the use of general anesthesia.
History of bleeding disorders, presence of brain metastases, or other intracranial abnormalities found on baseline radiologic imaging that would put them at risk for bleeding with anti-coagulation.
Known varices at risk of bleeding, including medium or large esophageal or gastric varices, active peptic ulcer, or history of recent hemoptysis.
Active second malignancy, or has history of recently definitively treated invasive cancer in the past 2 years prior to enrolment with the exception of non-melanoma skin cancer.
Peritoneal lesions or large abdominal masses.
Use of immunosuppressive drugs.
Inability to temporarily stop chronic anti-coagulation therapy.
Active bacterial infections with systemic manifestations.
Active viral infection, including Hepatitis B and Hepatitis C infection. NOTE: Patients with anti-hepatitis B core antibody (HBc) positive, or hepatitis B surface antigen (HBsAg) but DNA negative are allowed exception(s).
Severe allergic reaction to iodine contrast that cannot be controlled by premedication with antihistamines and steroids.
History of or known hypersensitivity to melphalan or the components of the melphalan/HDS system.
History of known hypersensitivity to heparin or the presence of heparin-induced thrombocytopenia.
Uncontrolled endocrine disorder including diabetes mellitus, hypothyroidism, or hyperthyroidism.
Received anti-cancer therapy including radiotherapy or investigational agent for any indication ≤ 30 days prior to randomization
Previous treatment with trifluridine-tipiracil.
History of allergic reactions attributed to compounds of similar composition to trifluridine/tipiracil or any of its excipients.
Hereditary problems of galactose intolerance, total lactase deficiency or glucosegalactose malabsorption.
History of allergic reactions or hypersensitivity to bevacizumab or any of its excipients.
History of hypersensitivity to Chinese Hamster Ovary cell products or other recombinant human or humanized antibodies.
Contraindications to bevacizumab, including uncontrolled hypertension, history of active fistula or bowel perforation (unless in the setting of a resected primary), history of CVA or arterial thrombotic event in the last 1 year, or history of venous thrombotic event in the last 30 days.
Evidence of hepatic vein or portal vein thrombosis
Prior chemoembolization or radioembolization to the liver or prior hepatic arterial infusion therapy

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Santa Monica?

Yes, this clinical trial (NCT06607458) has an active research site in Santa Monica, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Refractory Metastatic Colorectal Cancer Treatment Options in Santa Monica, CA

If you're searching for refractory metastatic colorectal cancer treatment options in Santa Monica, CA, this clinical trial (NCT06607458) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Santa Monica research site is actively enrolling participants for this clinical trial. You'll receive care from experienced refractory metastatic colorectal cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all refractory metastatic colorectal cancer clinical trials near you to find additional studies recruiting in your area.

More Colorectal Cancer Trials in Santa Monica, CA

See all colorectal cancer clinical trials recruiting in Santa Monica — not just this study.

Browse Colorectal Cancer Trials in Santa Monica →

Browse More Trials by Condition

Colorectal Cancer TrialsEssential Tremor TrialsRheumatoid Arthritis TrialsAnkylosing Spondylitis TrialsInterstitial Cystitis TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Santa Monica?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Santa Monica, CA